Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 20/20 | 1.00 |
| ▸ | WNT1 | P04628 | 18/20 | 1.00 |
| ▸ | GSK3B | P49841 | 17/20 | 1.00 |
| ▸ | CLK2 | P49760 | 3/20 | 0.75 |
| ▸ | CLK3 | P49761 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19517502 | 1.00 | DYRK1A (1.00) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL19516527 | 0.92 | DYRK1A (1.00) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL30003634 | 0.92 | DYRK1A (1.00) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL20950760 | 0.90 | DYRK1A (0.82) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL20951526 | 0.90 | DYRK1A (0.82) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL20948680 | 0.89 | DYRK1A (0.79) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL32665270 | 0.87 | DYRK1A (1.00) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL19516980 | 0.87 | DYRK1A (1.00) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL19540170 | 0.87 | DYRK1A (0.82) | DYRK1AWNT1GSK3BCLK2CLK3 | |
| SCHEMBL20947944 | 0.87 | DYRK1A (0.77) | DYRK1AWNT1GSK3BCLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022108-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2026-01-22 | — | — | US | disclosed |
| US-20220332698-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | TENARX, INC. | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022108-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | DYRK1A 2162/4885WNT1 1/4885GSK3B 8/4885 |
| US-20220332698-A1 | ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF | WNT1, WNT3, WNT3A | DYRK1A 1006/4885WNT1 1/4885GSK3B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.